AdvisorShares Psychedelics ETF
PSIL
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 4800 Montgomery Lane, Suite 150 Bethesda MD United States of America 20814
- IPO Date
- Sep 16, 2021
- CIK
- 0001408970
- Website
- advisorshares.com
- Similar Companies
- Business
- AdvisorShares Psychedelics ETF (NYSE Arca: PSIL) is an actively managed exchange-traded fund that provides dedicated investment exposure to the emerging psychedelics sector, focusing on biotechnology, pharmaceutical, and life sciences companies deriving the majority of their revenue or assets from psychedelic drugs and related therapies. The fund invests primarily in equities such as ATAI Life Sciences NV, Relmada Therapeutics Inc, Compass Pathways plc, Supernus Pharmaceuticals Inc, MindMed Inc (MNMD), Bright Minds Biosciences Inc, Alto Neuroscience Inc, Neurocrine Biosciences Inc, Cybin Inc, and VistaGen Therapeutics Inc, among others; it employs daily active management to opportunistically adjust holdings amid sector volatility and innovation, potentially using swap contracts for certain OTC or foreign-listed securities. Launched on September 15, 2021, PSIL trades on the NYSE Arca with daily transparency of holdings, intraday liquidity, and a net expense ratio of 0.99%; it is sponsored by AdvisorShares Investments LLC, headquartered in Bethesda, Maryland. PSIL targets long-term capital appreciation in the nascent psychedelics industry, which encompasses research and development of psychedelic medicines for mental health issues like depression, anxiety, addiction, and post-traumatic stress disorder, as well as neurological disorders. The portfolio emphasizes companies involved in psychedelic drug production, distribution, R&D, and supply chain activities, serving institutional and retail investors seeking alpha opportunities in this high-growth, regulated medical frontier. Geographically, holdings span U.S., Canadian, and international firms, reflecting global exposure to the sector. In recent developments, PSIL underwent a 1-for-10 reverse stock split effective September 10, 2024, reducing outstanding shares by approximately 90% while preserving shareholder value and boosting per-share net asset value. During the first quarter of 2025, the fund added new positions in Neuphoria Therapeutics Inc (NEUP), Pasithea Therapeutics Corp (KTTA), and Silo Pharma Inc (SILO), while exiting holdings in Lucy Scientific Discovery Inc, Psybio Therapeutics Corp, and Seelos Therapeutics Inc; top performers included Neuronetics Inc (+128.57%) and Quantum BioPharma Ltd (+113.88%). As of December 2025, assets under management stand at approximately $19.58 million, with the fund delivering strong year-to-date performance of +75.37% on a NAV basis through November 30, 2025.